This biopharmastock has sold off 48% this year, but the firm sees upside potential of 137% ahead.
An overly negative reception to clinical results could mean investors are missing out on potential upside for Syndax Pharmaceuticals , according to Goldman Sachs. The investment bank initiated coverage of the biopharmaceutical company on Wednesday with a buy rating, setting a 12-month price target of $30. This implies potential upside of 137% from the stock's Tuesday closing price of $12.65. Shares of Syndax have plummeted more than 48% so far this year.
mountain Syndax YTD chart "We view the extent of the market's negative response as reflected in SNDX shares around reporting of the topline AUGMENT-101 data as an overreaction," wrote analyst Chris Shibutani. Instead, he said that Syndax's current valuation offered an "especially attractive entry point for investors" as two of the firm's treatments enter the regulatory process ahead of commercialization.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Hurricane Lidia makes landfall near Puerto Vallarta packing 140-mph windsLidia has made landfall as an 'extremely dangerous' Category 4 hurricane with winds of 140 mph near the Mexican coastal resort of Puerto Vallarta.
続きを読む »
Malan smashes 140, England amass 364-9 v BangladeshOpener Dawid Malan smashed 140 and forged century-plus partnerships with Jonny Bairstow and Joe Root to help England rack up 364-9 against Bangladesh in their second match of the 50-overs World Cup on Tuesday.
続きを読む »
Goldman Sachs says Japan is a 'bright spot' right now and reveals some top stocksGoldman Sachs says one Japanese sector looks particularly good value, and its top picks include one stock on its conviction list.
続きを読む »
High rates will shave 0.5% from US GDP, prompt job losses: Goldman SachsHigher-for-longer interest rates will likely shave 0.5% from U.S. economic growth and may force unprofitable public companies to begin cutting their workforce, strategists at Goldman Sachs wrote in…
続きを読む »
Hedge funds, family offices among those turning to Goldman Sachs ETF Accelerator‘The next wave of growth in the ETF space is going to be the active ETF,’ says Goldman’s Lisa Mantil
続きを読む »
Here are 20 stocks I'm watching Tuesday, including Lilly, AMD and Goldman SachsThese are some of the tickers on Jim’s radar for Tuesday, Oct. 10, taken directly from his reporter’s notebook.
続きを読む »